Gyon Technologies Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gyon Technologies Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,333	Closed	-$1.83M	–	414
2022 Q4	$1.83M	Buy	+6,333	New	+$1.93M	0.68%	41
2022 Q3	–	Sell	-3,797	Closed	-$1.07M	–	616
2022 Q2	$1.07M	Buy	3,797 +254	+7%	+$68K	0.3%	105
2022 Q1	$925K	Buy	+3,543	New	+$841K	0.65%	47
2020 Q1	–	Sell	-1,883	Closed	-$412K	–	189
2019 Q4	$412K	Buy	+1,883	New	+$381K	0.27%	94

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyon Technologies Capital Management's VRTX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 6,333 shares — an estimated $1.83M sold.

Gyon Technologies Capital Management first reported a position in VRTX in Q4 2019 and held it in 4 quarters. The position peaked at $1.83M in Q4 2022. 1,208 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Gyon Technologies Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Gyon Technologies Capital Management sold 6,333 Vertex Pharmaceuticals shares in Q1 2023, an estimated $1.83M.
Gyon Technologies Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Gyon Technologies Capital Management's Vertex Pharmaceuticals position peaked at $1.83M in Q4 2022.
1,208 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.